When I first heard that we needed to upsize from our current base in Stevenage, I imagined that picking out a new office would be somewhat like choosing a new laptop. Most of the work would be upfront, checking through a list of requirements -[…]
If we were to believe the hype, peddled both within the media and by technology vendors, turning big data into enormous business benefit is simply a matter of writing a cheque and buying the latest, greatest analytics platform.
Pharmaceuticals are increasingly using predictive science as a platform for R&D. Critical to this approach is building models from non-clinical and clinical data. What makes this tough is that you have to integrate and interrogate multiple data[…]
Historically, in large pharmaceutical R&D operations, in vivo studies have occupied a slightly awkward position in terms of data management. Data from the earliest stages of research – high throughout experimentation and the like – while not without[…]
Try Googling “pharmaceutical crisis” and you’ll find a mass of dire statistics that lays bare the scale of the challenge facing Big Pharma. Recent years have seen key players undergo cycles of restructuring and though they can still make good money[…]
Volatility, Uncertainty, Complexity and Ambiguity (VUCA) started life as an acronym in the post-Cold-War world of the US Army. It is now an accurate label capturing the current global business environment. In the commercial world it is becoming[…]
Workflow automation is an established approach to drive business efficiency and productivity, but formalising and automating workflows in R&D is often more challenging than in other business functions. The innovation and creativity required in R&D[…]